Among several factors, we have proven that COX-2-synthesized PGE2 is pivotal in therapeutic effects of hMSCs against immune-related diseases, including inflammatory bowel disease and atopic dermatitis [14, 36–38]. Here, PTGS2 is linked to atopic eczema.